Human epidermal growth factor receptor 2 (HER2)
Human epidermal growth factor receptor 2 (HER2) is a transmembrane receptor tyrosine kinase of the ErbB/HER family, encoded by the ERBB2 gene on chromosome 17q12 and expressed as an approximately 185 kDa glycoprotein with an extracellular region, a single membrane-spanning segment, and an intracellular kinase domain.
Human epidermal growth factor receptor 2 (HER2) is a transmembrane receptor tyrosine kinase of the ErbB/HER family, encoded by the ERBB2 gene on chromosome 17q12 and expressed as an approximately 185 kDa glycoprotein with an extracellular region, a single membrane-spanning segment, and an intracellular kinase domain. Unlike its relatives, HER2 binds no known ligand and holds its extracellular region permanently in the open, dimerization-ready conformation the others adopt only after ligand binding — which makes it the preferred partner for EGFR (HER1), HER3 and HER4. Heterodimerization, most potently with HER3, activates the kinase and drives RAS/MAPK, Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT) and JAK/STAT3 signaling for proliferation, survival and migration. When ERBB2 is amplified, the resulting overexpression pushes dimerization by mass action and signals without ligand at all, an established oncogenic event in breast, gastric and gastroesophageal junction cancers associated with aggressive biology and higher recurrence risk.
Clinically HER2 is both a biomarker and a target. Immunohistochemistry and in situ hybridization classify tumors as HER2-positive, HER2-low or HER2-negative, and that status — assessed alongside estrogen and progesterone receptor expression in breast cancer, and alongside CD274 molecule scoring in gastric and gastroesophageal junction disease, where HER2-negative patients are candidates for PD-1/PD-L1 checkpoint inhibitors such as pembrolizumab or tislelizumab plus chemotherapy — determines first-line treatment. The HER2-low category exists because antibody-drug conjugates changed what counts as actionable: tumors below the threshold for antibody therapy still respond to a conjugate, since the receptor need only deliver a payload rather than carry the tumor's growth signal.
The therapeutic classes act at different points. The antibody trastuzumab binds domain IV, inhibiting signaling and shedding of the extracellular domain and recruiting antibody-dependent cellular cytotoxicity, while pertuzumab binds domain II to block dimerization directly, which is why the two are combined rather than substituted. Small-molecule tyrosine kinase inhibitors act on the intracellular kinase domain and, being small, generally reach brain metastases more readily than antibodies do. Antibody-drug conjugates such as ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) use HER2 binding to deliver a cytotoxic payload, the latter with a membrane-permeable drug that also kills neighboring antigen-negative cells. Because HER2 is expressed in cardiomyocytes, blocking it carries a characteristic risk of usually reversible cardiac dysfunction that requires monitoring. Poor penetration of full-length immunoglobulins into solid tumors motivates smaller engineered formats — radiolabeled or site-specifically conjugated fragments, often fused to albumin-binding domains — and HER2-directed chimeric antigen receptor T cells. Acquired resistance through compensatory signaling and heterogeneity within the tumor microenvironment remains the central limitation of all of it.
Where the papers sit
50 papers from the last 6 months study Human epidermal growth factor receptor 2 (HER2) directly · updated from PubMed 16 Nov 2026
Study type 4 clinical trials · 10 observational · 8 human data · 24 preclinical · 4 unclassified
Themes 6 themes · 1 paradigm shift
-
HER2-Directed Cancer Treatment
Treatment is moving beyond conventional trastuzumab and chemotherapy toward molecularly selected radiotherapy, antibody conjugates, and immune combinations in HER2-positive disease. Breast cancer studies focus on HER2-low versus HER2-positive biology, metastatic survival, brain metastases, and discordant response after neoadjuvant therapy. [47Sc]Sc-NOTA-trastuzumab and 177Lu-trastuzumab are being explored for resistant or metastatic tumors, while tucatinib remains a pharmacokinetic and clinical tool. Gastroesophageal studies pair zanidatamab or trastuzumab-based strategies with checkpoint blockade, but testing and real-world treatment remain inconsistent.
15 papers · 30%
-
HER2 and EGFR Targeting
HER2 and EGFR targeting is being pursued through engineered affibodies, antibody conjugates, photoimmunotherapy, and multi-target kinase inhibitors. Resistance biology is sharpening the rationale for blockade, including EGFR ectodomain mutations overcome by trastuzumab deruxtecan and NRG-1/ErbB2/Akt signaling in cardiac injury. Quinazolinone and quinolinone-thiazole compounds remain early antiproliferative leads, with caspase-mediated apoptosis as a recurring endpoint. Proximity labeling and radiometal approaches aim to improve receptor-directed delivery and molecular mapping.
9 papers · 18%
-
Engineered T-Cell Therapies
HER2-directed cellular immunotherapy is moving toward multispecific recognition, stronger T-cell recruitment, and better penetration of solid tumors. CAR-T designs use ligand motifs, bispecific engagers, or CCL19/CCR7 circuits to address antigen heterogeneity and suppressive microenvironments. A first-in-human HER2×CD3×CD28 engager and HER2 ECD mRNA-LNP vaccines extend the approach beyond conventional CAR-T cells, while CD8+ responses remain a key endpoint. In vivo assembly and progenitor-based manufacturing are being developed to broaden access and persistence.
9 papers · 18%
-
HER2-Targeted Conjugates
HER2-targeted conjugates are being optimized for more selective payload release, higher tumor delivery, and longer systemic exposure. Exatecan ADC adapters, cathepsin S-selective linkers, and sequential chemoselective conjugation platforms address stability and manufacturing limits. Trastuzumab-modified mRNA lipid nanoparticles and 177Lu-labeled HER2 Fab conjugates extend targeting to nucleic-acid delivery and radionuclide therapy, with albumin binding improving pharmacokinetics. HER2 expression and ERBB2 alterations in bladder and renal cancers are helping define where these platforms may be useful.
8 papers · 16%
-
HER2 Alterations in Lung Cancer
HER2-altered lung cancer is being defined as a treatment-relevant subgroup, especially in NSCLC with mutations or amplification. Pyrotinib plus apatinib and second-line trastuzumab deruxtecan provide clinical testing of targeted therapy, while co-occurring EGFR L858R and HER2 amplification complicate sequencing. Accurate immunohistochemical testing remains essential because cytology handling can change biomarker calls. ADC development is also expanding into small-cell lung cancer, but the optimal sequence and predictive markers remain open.
6 papers · 12%
-
Nucleic Acid HER2 Targeting
HER2 nucleic-acid platforms are combining targeted delivery with sensitive molecular detection. Peptide nucleic acid probes support pretargeted affibody delivery of cytotoxic payloads, while spherical nucleic acids seek stronger intracellular antisense activity with reduced systemic toxicity. Hairpin-enhanced CRISPR/Cas12a provides an ultrasensitive HER2 protein biosensor rather than a treatment. The common direction is toward modular, nuclease-resistant tools that improve selectivity or signal amplification.
3 papers · 6%
HER2 response and status in the primary breast tumour cannot be assumed to represent metastatic disease
The case of HER2-positive breast cancer treated with neoadjuvant HER2-directed therapy found marked response in the primary tumour but persistent viable, untreated-appearing axillary nodal metastases 42767788Sep, while the cohort of patients undergoing resection of breast-cancer brain metastases found receptor discordance between primary tumours and brain metastases 42474755Jul. Together, these findings overturn the assumption that the primary tumour reliably reflects HER2 biology or treatment efficacy throughout the patient’s disease. HER2 assessment and treatment-response evaluation therefore require independent attention to metastatic sites, with staging, prognosis, and treatment planning informed by possible inter-site heterogeneity.
Papers
The 50 papers from the last 6 months that study Human epidermal growth factor receptor 2 (HER2) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
HER2-Directed Cancer Treatment (15)
- Discordant pathologic response to neoadjuvant human epidermal growth factor receptor 2-directed therapy in primary breast tumour and axillary lymph node metastases. BMJ case reports · 21 Sept 2026 PMID 42767788
- Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer. Breast cancer research and treatment · 16 Sept 2026 PMID 42747633
- 177Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer. Molecular biomedicine · 14 Sept 2026 PMID 42734882
- Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study. Medicine · 22 Aug 2026 PMID 42629708
- Reprogramming HER2-Positive gastroesophageal cancer immune contexture with bispecific therapy: HERIZON-GEA-01. Med (New York, N.Y.) · 14 Aug 2026 PMID 42600568
- Development and characterization of [47Sc]Sc-NOTA-trastuzumab for targeted radiotherapy in primary and metastatic HER2 + breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 21 Jul 2026 PMID 42480146
- Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data. Journal of hematology & oncology · 21 Jul 2026 PMID 42477829
- Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment · 20 Jul 2026 PMID 42474755
- Beyond Amplification: Precision Approaches to Targeting HER2. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Jul 2026 PMID 42423636
- A Droplet-Microarray Platform for Multiplex Profiling of Breast Cancer Exosome Subtypes in Patients' Blood Plasma Samples. Small (Weinheim an der Bergstrasse, Germany) · 7 Jul 2026 PMID 42410964
- Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control. Medical oncology (Northwood, London, England) · 1 Jul 2026 PMID 42384122
- Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial. Breast (Edinburgh, Scotland) · 27 Jun 2026 PMID 42364416
- Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice. Biomedical chromatography : BMC · 22 Jun 2026 PMID 42328931
- Real-World Treatment Patterns, HER2 Testing Practices, and Clinical Outcomes in HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Advances in therapy · 30 May 2026 PMID 42217113
- Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. The New England journal of medicine · 27 May 2026 PMID 42202319
HER2 and EGFR Targeting (9)
- Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis. Scientific reports · 7 Sept 2026 PMID 42706361
- Cell Surface Deazaflavin-Diazirine Energy-Transfer (DarT) Photoproximity Labeling Using Antibody Conjugates. Bioconjugate chemistry · 19 Aug 2026 PMID 42615513
- SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
- Near-infrared Photoimmunotherapy Targeting Canine Mammary Tumors: Comparative Oncology for Overcoming Human Breast Cancer. Anticancer research · 29 Jul 2026 PMID 42527083
- Higher frequency of subclonal anti-EGFR resistance mutations in post-treatment samples from patients with colorectal cancer liver metastases following anti-EGFR-based conversion chemotherapy. PloS one · 6 Jul 2026 PMID 42406708
- Chelator-Free Radiometal Labeling Inside Engineered Affibodies. Angewandte Chemie (International ed. in English) · 4 Jun 2026 PMID 42237896
- Dimethyl fumarate attenuates post-infarct myocardial injury and is associated with modulation of the NRG-1/ErbB2/Akt pathway and reduction of oxidative stress. European journal of pharmacology · 2 Jun 2026 PMID 42229738
- Rationally designed quinazolinone derivatives incorporating acetyl pyridine and thiazole scaffolds as dual EGFR/HER-2 anticancer agents: integrated biological evaluation, molecular profiling, and advanced computational studies. Bioorganic chemistry · 30 May 2026 PMID 42217499
- EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer letters · 23 May 2026 PMID 42176792
Engineered T-Cell Therapies (9)
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. Journal for immunotherapy of cancer · 7 Sept 2026 PMID 42705861
- CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
- Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 30 Jun 2026 PMID 42378880
- Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. Cell reports. Medicine · 25 Jun 2026 PMID 42349416
- Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. Cell · 19 Jun 2026 PMID 42320470
- Deep-Learning Solution Providing Molecular Marker Subtyping of Breast Cancer Whole Slide Images: Protocol for a UK Clinical Service Evaluation Study. JMIR research protocols · 16 Jun 2026 PMID 42302265
- CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. International immunopharmacology · 6 Jun 2026 PMID 42250288
- Interplay of the IGFBP-3 polymorphism and serum levels of IGF-1/IGFBP-3 with hormone receptor subtypes in patients with breast cancer among Palestinian women. PloS one · 1 Jun 2026 PMID 42224209
- Efficient in vivo assembly of DNA encoded polyvalent BTEs for dual antigen targeting for broadening therapeutic impact in ovarian cancer. Molecular therapy : the journal of the American Society of Gene Therapy · 27 May 2026 PMID 42198849
HER2-Targeted Conjugates (8)
- Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer. Cancer science · 13 Sept 2026 PMID 42732768
- HER2 and Other ErbB Receptors' Expression and Their Involvement in the Oncogenesis of Clear Cell Renal Cell Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674699
- FcBP-HFQ lipid-mediated trastuzumab modification of mRNA-loaded lipid nanoparticles enhances delivery to HER2-expressing cancer cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 18 Aug 2026 PMID 42612711
- Albumin binding improves the pharmacokinetics and therapeutic efficacy of a 177Lu-labeled HER2 Fab radioconjugate. Science advances · 17 Jul 2026 PMID 42467791
- Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform. Angewandte Chemie (International ed. in English) · 8 Jul 2026 PMID 42417250
- Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. Journal of medicinal chemistry · 1 Jul 2026 PMID 42381118
- NH2-trimethyl lock (NH2-TML): a stable and effective adapter for exatecan-based antibody-drug conjugates. Bioorganic chemistry · 31 May 2026 PMID 42218895
- Placental transcriptome profiling and immune signature differences in pregnancies with and without gestational diabetes mellitus: An observational study. Medicine · 23 May 2026 PMID 42175401
HER2 Alterations in Lung Cancer (6)
- Preanalytical variables affect predictive immunohistochemical biomarker testing in non-small cell lung carcinoma cytology specimens. Cancer cytopathology · 9 Oct 2026 PMID 42851084
- First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial. Lung cancer (Amsterdam, Netherlands) · 3 Sept 2026 PMID 42691829
- Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling. The American journal of case reports · 2 Sept 2026 PMID 42681853
- Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway. Antimicrobial agents and chemotherapy · 30 Jun 2026 PMID 42376990
- Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan. Lung cancer (Amsterdam, Netherlands) · 9 Jun 2026 PMID 42263332
- "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers. Cancer discovery · 5 Jun 2026 PMID 42249527
Nucleic Acid HER2 Targeting (3)
- Zwitterionic Brush-Engineered Molecular Spherical Nucleic Acids for Enhanced Intracellular Antisense Activity. Nano letters · 9 Sept 2026 PMID 42715048
- Peptide Nucleic Acid Probes for Pretargeted Affibody-Mediated Delivery of Cytotoxic Payloads to HER2-Positive Carcinoma. Bioconjugate chemistry · 19 Aug 2026 PMID 42615509
- Tribos: A Modular Hairpin-Enhanced CRISPR/Cas12a Biosensor for Ultrasensitive Detection of HER2 Protein. Analytical chemistry · 9 Jul 2026 PMID 42424600
By study type
Clinical trials (4)
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors. Journal for immunotherapy of cancer · 7 Sept 2026 PMID 42705861
- First-line pyrotinib plus apatinib in advanced non-small cell lung cancer harboring HER2 mutations or amplification: a phase II trial. Lung cancer (Amsterdam, Netherlands) · 3 Sept 2026 PMID 42691829
- Dose-dense adjuvant chemotherapy in HER2-low breast cancer: An exploratory analysis of the GIM2 trial. Breast (Edinburgh, Scotland) · 27 Jun 2026 PMID 42364416
- Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. The New England journal of medicine · 27 May 2026 PMID 42202319
Observational studies and case reports (10)
- Preanalytical variables affect predictive immunohistochemical biomarker testing in non-small cell lung carcinoma cytology specimens. Cancer cytopathology · 9 Oct 2026 PMID 42851084
- Discordant pathologic response to neoadjuvant human epidermal growth factor receptor 2-directed therapy in primary breast tumour and axillary lymph node metastases. BMJ case reports · 21 Sept 2026 PMID 42767788
- Metastatic phenotype and post-metastatic survival across HER2-0, HER2-low, and HER2-positive breast cancer. Breast cancer research and treatment · 16 Sept 2026 PMID 42747633
- Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling. The American journal of case reports · 2 Sept 2026 PMID 42681853
- Prognostic factors and outcomes associated with postmastectomy radiation therapy following neoadjuvant chemotherapy and mastectomy for breast cancer: A retrospective cohort study. Medicine · 22 Aug 2026 PMID 42629708
- Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment · 20 Jul 2026 PMID 42474755
- Higher frequency of subclonal anti-EGFR resistance mutations in post-treatment samples from patients with colorectal cancer liver metastases following anti-EGFR-based conversion chemotherapy. PloS one · 6 Jul 2026 PMID 42406708
- Deep-Learning Solution Providing Molecular Marker Subtyping of Breast Cancer Whole Slide Images: Protocol for a UK Clinical Service Evaluation Study. JMIR research protocols · 16 Jun 2026 PMID 42302265
- Interplay of the IGFBP-3 polymorphism and serum levels of IGF-1/IGFBP-3 with hormone receptor subtypes in patients with breast cancer among Palestinian women. PloS one · 1 Jun 2026 PMID 42224209
- Placental transcriptome profiling and immune signature differences in pregnancies with and without gestational diabetes mellitus: An observational study. Medicine · 23 May 2026 PMID 42175401
Human data, design not indexed (8)
- Reprogramming HER2-Positive gastroesophageal cancer immune contexture with bispecific therapy: HERIZON-GEA-01. Med (New York, N.Y.) · 14 Aug 2026 PMID 42600568
- SMARCA2 and SMARCA4-deficiency is associated with a distinct molecular and microenvironmental subtype of esophageal adenocarcinoma. Scientific reports · 29 Jul 2026 PMID 42527418
- Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and pooled analysis of individual patient-level data. Journal of hematology & oncology · 21 Jul 2026 PMID 42477829
- Tribos: A Modular Hairpin-Enhanced CRISPR/Cas12a Biosensor for Ultrasensitive Detection of HER2 Protein. Analytical chemistry · 9 Jul 2026 PMID 42424600
- Beyond Amplification: Precision Approaches to Targeting HER2. Clinical cancer research : an official journal of the American Association for Cancer Research · 9 Jul 2026 PMID 42423636
- A Droplet-Microarray Platform for Multiplex Profiling of Breast Cancer Exosome Subtypes in Patients' Blood Plasma Samples. Small (Weinheim an der Bergstrasse, Germany) · 7 Jul 2026 PMID 42410964
- "Outstanding" ADC Candidates Emerge for SCLC, Other Cancers. Cancer discovery · 5 Jun 2026 PMID 42249527
- Chelator-Free Radiometal Labeling Inside Engineered Affibodies. Angewandte Chemie (International ed. in English) · 4 Jun 2026 PMID 42237896
Preclinical: animal, cell and lab studies (24)
- 177Lu-trastuzumab radionuclide therapy: a promising strategy for trastuzumab-resistant brain metastases in HER2+ breast cancer. Molecular biomedicine · 14 Sept 2026 PMID 42734882
- Zwitterionic Brush-Engineered Molecular Spherical Nucleic Acids for Enhanced Intracellular Antisense Activity. Nano letters · 9 Sept 2026 PMID 42715048
- Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis. Scientific reports · 7 Sept 2026 PMID 42706361
- HER2 and Other ErbB Receptors' Expression and Their Involvement in the Oncogenesis of Clear Cell Renal Cell Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674699
- Cell Surface Deazaflavin-Diazirine Energy-Transfer (DarT) Photoproximity Labeling Using Antibody Conjugates. Bioconjugate chemistry · 19 Aug 2026 PMID 42615513
- Peptide Nucleic Acid Probes for Pretargeted Affibody-Mediated Delivery of Cytotoxic Payloads to HER2-Positive Carcinoma. Bioconjugate chemistry · 19 Aug 2026 PMID 42615509
- Near-infrared Photoimmunotherapy Targeting Canine Mammary Tumors: Comparative Oncology for Overcoming Human Breast Cancer. Anticancer research · 29 Jul 2026 PMID 42527083
- Development and characterization of [47Sc]Sc-NOTA-trastuzumab for targeted radiotherapy in primary and metastatic HER2 + breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 21 Jul 2026 PMID 42480146
- CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas. Molecular therapy : the journal of the American Society of Gene Therapy · 21 Jul 2026 PMID 42478044
- Albumin binding improves the pharmacokinetics and therapeutic efficacy of a 177Lu-labeled HER2 Fab radioconjugate. Science advances · 17 Jul 2026 PMID 42467791
- Modular Assembly of Bioconjugates Enabled by a Pyridine-Based Chemoselective Sequential Conjugation Platform. Angewandte Chemie (International ed. in English) · 8 Jul 2026 PMID 42417250
- Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control. Medical oncology (Northwood, London, England) · 1 Jul 2026 PMID 42384122
- Engineering Cathepsin S Selective Chemical Probes and Antibody-Drug Conjugates through Substrate Profiling with Unnatural Amino Acids. Journal of medicinal chemistry · 1 Jul 2026 PMID 42381118
- Tailored HER2 ECD mRNA-LNP vaccines boost CD8+ T cell-mediated antitumor immunity for HER2-positive tumor suppression. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 30 Jun 2026 PMID 42378880
- Anti-RSV drug screening and inhibition of RSV infection by lapatinib through the IL-17 pathway. Antimicrobial agents and chemotherapy · 30 Jun 2026 PMID 42376990
- Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors. Cell reports. Medicine · 25 Jun 2026 PMID 42349416
- Quantitation of Tucatinib, a Novel Tyrosine Kinase Inhibitor in Dried Blood Spot (DBS) With LC-ESI-MS/MS: Application to a Pharmacokinetic Study in Mice. Biomedical chromatography : BMC · 22 Jun 2026 PMID 42328931
- Expansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapy. Cell · 19 Jun 2026 PMID 42320470
- CCL19-armed oncolytic adenovirus synergizes with CCR7-expressing CAR-T cells to suppress ovarian tumor growth. International immunopharmacology · 6 Jun 2026 PMID 42250288
- Dimethyl fumarate attenuates post-infarct myocardial injury and is associated with modulation of the NRG-1/ErbB2/Akt pathway and reduction of oxidative stress. European journal of pharmacology · 2 Jun 2026 PMID 42229738
- NH2-trimethyl lock (NH2-TML): a stable and effective adapter for exatecan-based antibody-drug conjugates. Bioorganic chemistry · 31 May 2026 PMID 42218895
- Rationally designed quinazolinone derivatives incorporating acetyl pyridine and thiazole scaffolds as dual EGFR/HER-2 anticancer agents: integrated biological evaluation, molecular profiling, and advanced computational studies. Bioorganic chemistry · 30 May 2026 PMID 42217499
- Efficient in vivo assembly of DNA encoded polyvalent BTEs for dual antigen targeting for broadening therapeutic impact in ovarian cancer. Molecular therapy : the journal of the American Society of Gene Therapy · 27 May 2026 PMID 42198849
- EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan. Cancer letters · 23 May 2026 PMID 42176792
Unclassified: not yet indexed with MeSH (4)
- Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer. Cancer science · 13 Sept 2026 PMID 42732768
- FcBP-HFQ lipid-mediated trastuzumab modification of mRNA-loaded lipid nanoparticles enhances delivery to HER2-expressing cancer cells. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 18 Aug 2026 PMID 42612711
- Real-world clinical characteristics and outcomes in patients with HER2-mutant non-small cell lung cancer (NSCLC) who received second-line treatment: A nationwide database analysis in Japan. Lung cancer (Amsterdam, Netherlands) · 9 Jun 2026 PMID 42263332
- Real-World Treatment Patterns, HER2 Testing Practices, and Clinical Outcomes in HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Advances in therapy · 30 May 2026 PMID 42217113
Written from 50 PubMed abstracts, each one listed by PMID above. Published: 2026-07-23. Last written: 2026-09-23 by GPT. Corrections: 2026-09-26 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.